Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.50 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31335961 | 1.00 | MAPT (0.62) | MAPTTDP1KDM4EMAPK1HSD17B10 | |
| SCHEMBL4143348 | 0.85 | MAPT (0.68) | MAPTTDP1KDM4EMAPK1HSD17B10 | |
| SCHEMBL3189109 | 0.84 | MAPT (0.72) | MAPTTDP1KDM4EMAPK1HSD17B10 | |
| SCHEMBL29378830 | 0.84 | MAPT (0.72) | MAPTTDP1KDM4EMAPK1HSD17B10 | |
| SCHEMBL732725 | 0.84 | MAPT (0.61) | MAPTTDP1KDM4EMAPK1HSD17B10 | |
| SCHEMBL19615906 | 0.83 | MAPT (0.47) | MAPTTDP1KDM4EMAPK1HSD17B10 | |
| SCHEMBL30466426 | 0.81 | MAPT (0.68) | MAPTTDP1KDM4EMAPK1HSD17B10 | |
| SCHEMBL2425023 | 0.81 | MAPT (0.68) | MAPTTDP1KDM4EMAPK1HSD17B10 | |
| SCHEMBL11026756 | 0.81 | MAPT (0.73) | MAPTTDP1KDM4EMAPK1HSD17B10 | |
| SCHEMBL27822908 | 0.81 | CA12 (0.57) | MAPTTDP1KDM4EMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017199227-A1 | PROCESS FOR PREPARATION OF 3,4-DIHYDROXY-2-METHYL BENZOIC ACID ALKYLESTER | S & I OPHTHALMIC, LLC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2023092212-A1 | FLAVOURING AGENT, COMPOSITION, PRODUCTION METHOD AND USE OF AROMATISING AND FLAVOURING AGENTS BASED ON VANILLA EXTRACTS | UNIVERSIDADE FEDERAL DO ESTADO DO RIO DE JANEIRO (BR) | 2023-06-01 | — | — | WO | disclosed |
| CN-111620764-B | Selective ether bond cleavage method of aryl alkyl ether | 荆楚理工学院 | 2023-05-05 | — | — | CN | disclosed |
| WO-2017199227-A1 | PROCESS FOR PREPARATION OF 3,4-DIHYDROXY-2-METHYL BENZOIC ACID ALKYLESTER | S & I OPHTHALMIC, LLC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017050928-A1 | PROCESS FOR MANUFACTURING COOKED MEAT PRODUCTS | PURAC BIOCHEM BV (NL) | 2017-03-30 | — | — | WO | disclosed |
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| CN-102746242-A | Synthesis method of 6, 7-substituent-4-aniline quinazoline | OMEGA CO LTD | 2012-10-24 | — | — | CN | disclosed |
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1572215-A1 | BENZO[D]AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056369-A1 | BENZO ‘ D!AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0607373-B1 | TRISUBSTITUTED PHENYL DERIVATIVES AS SELECTIVE PHOSPHODIESTERASE IV INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1997-03-19 | — | — | EP | disclosed |
| US-5340827-A | Phenylcarboxamide compounds which have useful pharmaceutical activity | CELLTECH, LIMITED (GB) | 1994-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | MAPT 866/4885TDP1 1488/4885KDM4E 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.